New Insights into Uric Acid Effects on the Progression and Prognosis of Chronic Kidney Disease

REFERENCES

• Davies Jr NS. The cardiovascular and renal relations and manifestations of gout. J Am Med Assoc. 1897;29:261.
   Google Scholar
• Nakagawa T, Kang DH, Feig D, . Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int. 2006;69:1722–1725.
   PubMed Web of Science ®Google Scholar
• Mahomed FA. On chronic Bright’s disease and its essential symptoms. Lancet. 1879;1:399–401.
   Google Scholar
• Haig A. On uric acid and arterial tension. BMJ. 1889;1:288–291.
   Google Scholar
• Huchard H. Arteriolosclerosis: Including its cardiac form. J Am Med Assoc. 1909;53:1129–1132.
   Google Scholar
• Berger L, Yü T. Renal function in gout: An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605–613.
   PubMed Web of Science ®Google Scholar
• Talbot JH, Terplan KL. The kidney in gout. Medicine. 1960;39:405–467.
   Google Scholar
• Gonick HC, Rubini MD, Gleason IO, Sommers SC. The renal lesion in gout. Ann Int Med. 1965;62:667–674.
   Google Scholar
• Beck L. Requiem for gouty nephropathy. Kidney Int. 1986;30:280–287.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Kivlighn SD, Kim Y-G, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular and renal disease. Am J Kidney Dis. 1999;33:225–234.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Kang DH, Feig D, . Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? J Am Soc Nephrol. 2003;41:1183–1190.
   Google Scholar
• Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: Implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol. 2005;70:343–354.
   PubMed Web of Science ®Google Scholar
• Hink HU, Santanam N, Dikalov S, . Peroxidase properties of extracellular superoxide dismutase: Role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002;22:1402–1408.
   PubMed Web of Science ®Google Scholar
• Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis. 2000;148:131–139.
   PubMed Web of Science ®Google Scholar
• Filiopoulos V, Hadjiyannakos D, Metaxaki P, . Inflammation and oxidative stress in patients on hemodiafiltration. Am J Nephrol. 2008;28(6):949–957.
   Google Scholar
• Nakagawa T, Mazzali M, Kang DH, Sanchez-Lozada LG, Herrara-Acosta J, Johnson RJ. Uric acid: A uremic toxin? Blood Purif. 2006;24:67–70.
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T, Feng L, . A role of uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888–2897.
   PubMed Web of Science ®Google Scholar
• Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid induced C-reactive protein (CRP) expression: Implication on cell proliferation and nitric oxide production in human vascular cells. J Am Soc Nephrol. 2005;16:3553–3562.
   PubMed Web of Science ®Google Scholar
• Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol. 2000;49:511.
   Google Scholar
• Glinsberg MH, Kozin F, O’Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Invest. 1997;60:999–1007.
   Google Scholar
• Feig D, Mazzali M, Kang DH, . Serum uric acid: A risk factor and a target for treatment? J Am Soc Nephrol. 2006;17:69–73.
   Web of Science ®Google Scholar
• Feig D, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Eng J Med. 2008;359:1811–1821.
   PubMed Web of Science ®Google Scholar
• Jossa F, Farinaro E, Panico S, . Serum uric acid and hypertension. The Olivetti heart study. J Hum Hypertens. 1994;8:677–681.
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971–1992. J Am Med Assoc. 2000;283:2404–2410.
   PubMed Web of Science ®Google Scholar
• Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men. The Osaka Health Survey. J Hypertens. 2001;19:1209–1215.
   PubMed Web of Science ®Google Scholar
• De Leeuw PW, Thijs L, Birkenhäger WH, . Prognostic significance of renal function in elderly patients with isolated systolic hypertension: Results from the Syst-Eur Trial. J Am Soc Nephrol. 2002;13:2213–2222.
   PubMed Web of Science ®Google Scholar
• Bickel C, Rupprecht HJ, Blankenberg S, . Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:12–17.
   PubMed Web of Science ®Google Scholar
• Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–480.
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Okamato M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and the risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523–530.
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Sullivan L, D’Agostino R, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension. 2005;45:28–33.
   PubMed Web of Science ®Google Scholar
• Culleton BF, Larson MG, Kannel WB, . Serum uric acid and risk for cardiovascular and death: The Framingham Heart Study. Ann Intern Med. 1999;131:7–13.
   PubMed Web of Science ®Google Scholar
• Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WE. Serum uric acid and risk of coronary heart disease: Atherosclerosis risk in communities (ARIC) Study. Ann Epidemiol. 2000;10:136–143.
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Beddhu S. Associations of uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant. 2009;24:1260–1266.
   PubMedGoogle Scholar
• Neri L, Rocca Rey LA, Lentine KL, . Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: A historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis. 2011;58:398–408.
   Google Scholar
• Kahn HA, Medalie JH, Neufeld HN, Riss E, Goldbourt U. The incidence of hypertension and associated factors: The Israel ischemic heart study. Am Heart J. 1972;84:171–182.
   PubMed Web of Science ®Google Scholar
• Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457–464.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med. 1973;132:401–410.
   PubMed Web of Science ®Google Scholar
• Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med. 1988;85:134–138.
   PubMed Web of Science ®Google Scholar
• Pearson T, Blair S, Daniels S, . AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388–391.
   PubMed Web of Science ®Google Scholar
• Chobanian A, Bakris G, Black H, . National Heart, Lung, and Blood Institute; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. J Am Med Assoc. 2003;289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim YG, . Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101–1106.
   PubMed Web of Science ®Google Scholar
• Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007;18:287–292.
   PubMed Web of Science ®Google Scholar
• Kaplan NM, Opie LH. Controversies in hypertension. Lancet. 2006;367:168–176.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Feig DI. Hyperuricemia in childhood essential hypertension. Hypertension. 2003;42:247–252.
   Google Scholar
• Silverstein DM, Srivaths PR, Mattison P, . Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients. Pediatr Nephrol. 2011;26:1123–1128.
   Google Scholar
• Tseng CH. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int. 2005;68:796–801.
   PubMed Web of Science ®Google Scholar
• Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest. 2001;31:318–321.
   Google Scholar
• Syrjänen J, Mustonen J, Pasternak A. Hypertriglyceridemia and hyperuricemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15:34–42.
   PubMedGoogle Scholar
• Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M. Serum uric acid and renal prognosis in IgA nephropathy. Nephron. 2001;87:333–339.
   PubMed Web of Science ®Google Scholar
• Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–697.
   PubMed Web of Science ®Google Scholar
• Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642–650.
   PubMed Web of Science ®Google Scholar
• Domrongkitchaiporn S, Sritara P, Kitiyakara C, . Risk factors for development of decreased kidney function in a Southeast Asian population: A 12-year cohort study. J Am Soc Nephrol. 2005;16:791–799.
   PubMed Web of Science ®Google Scholar
• Ishani A, Grandits GA, Grimm RH, . Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol. 2006;17:1444–1452.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470.
   PubMed Web of Science ®Google Scholar
• Conchol MB, Shlipak MG, Katz R, . Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50:239–247.
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19:1204–1211.
   PubMed Web of Science ®Google Scholar
• Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407–2413.
   PubMed Web of Science ®Google Scholar
• Ben-Dov IZ, Kark JD. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant. 2011;26:2558–2566.
   PubMedGoogle Scholar
• Madero M, Sarnak MJ, Wang X, . Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53:796–803.
   PubMed Web of Science ®Google Scholar
• Sturm G, Kollerits B, Neyer U, Ritz E, Kronemberg F, MMKD Study Group. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43:347–352.
   PubMed Web of Science ®Google Scholar
• Mohandas R, Johnson RJ. Uric acid levels increase risk for new-onset kidney disease. J Am Soc Nephrol. 2008;19:2251–2253.
   Google Scholar
• Bradley A, Caskey CT. Hyperuricemia and urate nephropathy in urate oxidase deficient mice. Proc Natl Acad Sci USA. 1994;91:742–746.
   Google Scholar
• Nakagawa T, Mazzali M, Kang DH, . Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23:2–7.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Kang DH, Feng L, . Uric acid, hominoid evolution, and the pathogenesis salt-sensitivity. Hypertension. 2002;40:355–360.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346:913–923.
   PubMed Web of Science ®Google Scholar
• Mazzali M, Kanellis J, Han L, . Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991–F997.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Tapia E, Santamaria J, . Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67:237–247.
   PubMed Web of Science ®Google Scholar
• Mazzali M, Kim Y-G, Suga S, . Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation. 2001;71:900–905.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1:80–86.
   PubMedGoogle Scholar
• Nakagawa T, Hu H, Zharikov S, . A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290:F625–F631.
   PubMed Web of Science ®Google Scholar
• Cirillo P, Sato W, Reungjui S, . Uric acid, the metabolic syndrome and renal disease. J Am Soc Nephrol. 2006;17:165–168.
   PubMed Web of Science ®Google Scholar
• Taalat KM, El-Sheikh AR. The effect of mild hyperuricaemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27:435–440.
   Google Scholar
• Kanbay M, Ozkara A, Selcoki Y, . Effect of treatment of hyperuricaemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227–1233.
   PubMed Web of Science ®Google Scholar
• Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–59.
   PubMed Web of Science ®Google Scholar
• Afshari M, Larijani B, Rezaie A, . Ineffectiveness of allopourinol in reduction of oxidative stress in diabetic patients; A randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother. 2004;58:546–550.
   PubMed Web of Science ®Google Scholar
• Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746–751.
   PubMed Web of Science ®Google Scholar
• Kao MP, Ang DS, Gandy SJ, . Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22:1382–1389.
   PubMed Web of Science ®Google Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, . The impact of serum uric acid in cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041–1049.
   PubMed Web of Science ®Google Scholar
• Miao Y, Ottenbros SA, Laverman GD, . Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58:2–7.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, . Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–1393.
   PubMed Web of Science ®Google Scholar
• Halevy S, Ghislain PD, Mockenhaupt M, . Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25–32.
   PubMed Web of Science ®Google Scholar
• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure in adolescents with newly diagnosed essential hypertension: A randomized trial. J Am Med Assoc. 2008;300(8):924–932.
   PubMed Web of Science ®Google Scholar
• Neal DA, Tom BD, Gimson AE, . Hyperuricemia, gout and renal function after liver transplantation. Transplantation. 2001;72:1689–1691.
   PubMed Web of Science ®Google Scholar
• Saglam F, Celic A, Sarioglu S, . Hyperuricemia influences chronic cyclosporine nephropathy. Transplant Proc. 2008;40(1):167–170.
   Google Scholar
• Akalin E, Ganeshan SV, Winston J, Muntner P. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation. 2008;86(5):652–658.
   PubMed Web of Science ®Google Scholar
• Ejaz AA, Mu W, Kang DH, . Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol. 2007;2:16–21.
   PubMed Web of Science ®Google Scholar